Serious adverse events (SAEs) included anemia (6.5%), thrombocytopenia (6.5%), alanine aminotransferase increased (6.5%), neutropenia (3.2%), anorexia (3.2%), fatigue (3.2%), hypokalemia (3.2%), and hypocalcemia (3.2%), occurred in seven (22.6%) patients, and all recovered after best supportive care. This evidence concerns the gene GPT and anemia (phenotype).